FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361825302> ?p ?o ?g. }

• W4361825302 abstract "<div>Abstract<p>The family of PIM serine/threonine kinases includes three highly conserved oncogenes, <i>PIM1, PIM2,</i> and <i>PIM3</i>, which regulate multiple prosurvival pathways and cooperate with other oncogenes such as <i>MYC</i>. Recent genomic CRISPR-Cas9 screens further highlighted oncogenic functions of PIMs in diffuse large B-cell lymphoma (DLBCL) cells, justifying the development of small-molecule PIM inhibitors and therapeutic targeting of PIM kinases in lymphomas. However, detailed consequences of PIM inhibition in DLBCL remain undefined. Using chemical and genetic PIM blockade, we comprehensively characterized PIM kinase–associated prosurvival functions in DLBCL and the mechanisms of PIM inhibition–induced toxicity. Treatment of DLBCL cells with SEL24/MEN1703, a pan-PIM inhibitor in clinical development, decreased BAD phosphorylation and cap-dependent protein translation, reduced MCL1 expression, and induced apoptosis. PIM kinases were tightly coexpressed with MYC in diagnostic DLBCL biopsies, and PIM inhibition in cell lines and patient-derived primary lymphoma cells decreased MYC levels as well as expression of multiple MYC-dependent genes, including <i>PLK1</i>. Chemical and genetic PIM inhibition upregulated surface CD20 levels in an MYC-dependent fashion. Consistently, MEN1703 and other clinically available pan-PIM inhibitors synergized with the anti-CD20 monoclonal antibody rituximab <i>in vitro</i>, increasing complement-dependent cytotoxicity and antibody-mediated phagocytosis. Combined treatment with PIM inhibitor and rituximab suppressed tumor growth in lymphoma xenografts more efficiently than either drug alone. Taken together, these results show that targeting PIM in DLBCL exhibits pleiotropic effects that combine direct cytotoxicity with potentiated susceptibility to anti-CD20 antibodies, justifying further clinical development of such combinatorial strategies.</p>Significance:<p>These findings demonstrate that inhibition of PIM induces DLBCL cell death via MYC-dependent and -independent mechanisms and enhances the therapeutic response to anti-CD20 antibodies by increasing CD20 expression.</p></div>" @default.
• W4361825302 created "2023-04-05" @default.
• W4361825302 creator A5000974993 @default.
• W4361825302 creator A5001381388 @default.
• W4361825302 creator A5002278917 @default.
• W4361825302 creator A5015594851 @default.
• W4361825302 creator A5018510629 @default.
• W4361825302 creator A5020023524 @default.
• W4361825302 creator A5025138388 @default.
• W4361825302 creator A5027562779 @default.
• W4361825302 creator A5031962066 @default.
• W4361825302 creator A5032817856 @default.
• W4361825302 creator A5033724279 @default.
• W4361825302 creator A5038071269 @default.
• W4361825302 creator A5038728330 @default.
• W4361825302 creator A5038751267 @default.
• W4361825302 creator A5046478756 @default.
• W4361825302 creator A5047523400 @default.
• W4361825302 creator A5051771291 @default.
• W4361825302 creator A5054788838 @default.
• W4361825302 creator A5060605798 @default.
• W4361825302 creator A5061008099 @default.
• W4361825302 creator A5061408064 @default.
• W4361825302 creator A5062552416 @default.
• W4361825302 creator A5062680236 @default.
• W4361825302 creator A5062932374 @default.
• W4361825302 creator A5065430527 @default.
• W4361825302 creator A5070593203 @default.
• W4361825302 creator A5076415765 @default.
• W4361825302 creator A5077983441 @default.
• W4361825302 creator A5082007741 @default.
• W4361825302 creator A5084411623 @default.
• W4361825302 creator A5086914724 @default.
• W4361825302 creator A5088184588 @default.
• W4361825302 creator A5091705408 @default.
• W4361825302 date "2023-03-31" @default.
• W4361825302 modified "2023-10-17" @default.
• W4361825302 title "Data from Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies" @default.
• W4361825302 doi "https://doi.org/10.1158/0008-5472.c.6513748.v1" @default.
• W4361825302 hasPublicationYear "2023" @default.
• W4361825302 type Work @default.
• W4361825302 citedByCount "0" @default.
• W4361825302 crossrefType "posted-content" @default.
• W4361825302 hasAuthorship W4361825302A5000974993 @default.
• W4361825302 hasAuthorship W4361825302A5001381388 @default.
• W4361825302 hasAuthorship W4361825302A5002278917 @default.
• W4361825302 hasAuthorship W4361825302A5015594851 @default.
• W4361825302 hasAuthorship W4361825302A5018510629 @default.
• W4361825302 hasAuthorship W4361825302A5020023524 @default.
• W4361825302 hasAuthorship W4361825302A5025138388 @default.
• W4361825302 hasAuthorship W4361825302A5027562779 @default.
• W4361825302 hasAuthorship W4361825302A5031962066 @default.
• W4361825302 hasAuthorship W4361825302A5032817856 @default.
• W4361825302 hasAuthorship W4361825302A5033724279 @default.
• W4361825302 hasAuthorship W4361825302A5038071269 @default.
• W4361825302 hasAuthorship W4361825302A5038728330 @default.
• W4361825302 hasAuthorship W4361825302A5038751267 @default.
• W4361825302 hasAuthorship W4361825302A5046478756 @default.
• W4361825302 hasAuthorship W4361825302A5047523400 @default.
• W4361825302 hasAuthorship W4361825302A5051771291 @default.
• W4361825302 hasAuthorship W4361825302A5054788838 @default.
• W4361825302 hasAuthorship W4361825302A5060605798 @default.
• W4361825302 hasAuthorship W4361825302A5061008099 @default.
• W4361825302 hasAuthorship W4361825302A5061408064 @default.
• W4361825302 hasAuthorship W4361825302A5062552416 @default.
• W4361825302 hasAuthorship W4361825302A5062680236 @default.
• W4361825302 hasAuthorship W4361825302A5062932374 @default.
• W4361825302 hasAuthorship W4361825302A5065430527 @default.
• W4361825302 hasAuthorship W4361825302A5070593203 @default.
• W4361825302 hasAuthorship W4361825302A5076415765 @default.
• W4361825302 hasAuthorship W4361825302A5077983441 @default.
• W4361825302 hasAuthorship W4361825302A5082007741 @default.
• W4361825302 hasAuthorship W4361825302A5084411623 @default.
• W4361825302 hasAuthorship W4361825302A5086914724 @default.
• W4361825302 hasAuthorship W4361825302A5088184588 @default.
• W4361825302 hasAuthorship W4361825302A5091705408 @default.
• W4361825302 hasBestOaLocation W43618253022 @default.
• W4361825302 hasConcept C11960822 @default.
• W4361825302 hasConcept C184235292 @default.
• W4361825302 hasConcept C185592680 @default.
• W4361825302 hasConcept C203014093 @default.
• W4361825302 hasConcept C2776414213 @default.
• W4361825302 hasConcept C2778559949 @default.
• W4361825302 hasConcept C2779338263 @default.
• W4361825302 hasConcept C502942594 @default.
• W4361825302 hasConcept C86803240 @default.
• W4361825302 hasConcept C95444343 @default.
• W4361825302 hasConcept C98175054 @default.
• W4361825302 hasConceptScore W4361825302C11960822 @default.
• W4361825302 hasConceptScore W4361825302C184235292 @default.
• W4361825302 hasConceptScore W4361825302C185592680 @default.
• W4361825302 hasConceptScore W4361825302C203014093 @default.
• W4361825302 hasConceptScore W4361825302C2776414213 @default.
• W4361825302 hasConceptScore W4361825302C2778559949 @default.
• W4361825302 hasConceptScore W4361825302C2779338263 @default.
• W4361825302 hasConceptScore W4361825302C502942594 @default.
• W4361825302 hasConceptScore W4361825302C86803240 @default.
• W4361825302 hasConceptScore W4361825302C95444343 @default.
• W4361825302 hasConceptScore W4361825302C98175054 @default.
• W4361825302 hasLocation W43618253021 @default.

• next